These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment of refractory and/or severe ANCA-associated systemic necrotizing vasculitides. Guillevin L; Pagnoux C Isr Med Assoc J; 2008 Jan; 10(1):89-91. PubMed ID: 18300585 [TBL] [Abstract][Full Text] [Related]
4. [Off-label use of biological therapies in systemic diseases]. Hachulla E Rev Med Interne; 2010 Dec; 31 Suppl 3():S307-14. PubMed ID: 21036424 [No Abstract] [Full Text] [Related]
5. [Twenty-seven years' activities of the French vasculitis study group (FVSG)]. Guillevin L Rev Med Interne; 2007 Dec; 28 Suppl 4():S263-5. PubMed ID: 18029060 [No Abstract] [Full Text] [Related]
7. Advances in the use of biologic agents for the treatment of systemic vasculitis. Chung SA; Seo P Curr Opin Rheumatol; 2009 Jan; 21(1):3-9. PubMed ID: 19077713 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapies in dermatologic disorders. Fallen RS; Terpstra CR; Lima HC Med Clin North Am; 2012 May; 96(3):565-82, x-xi. PubMed ID: 22703856 [TBL] [Abstract][Full Text] [Related]
9. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept. Weinberg JM; Saini R Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627 [TBL] [Abstract][Full Text] [Related]
11. [Vasculitis: update 2014]. Fleck M; Aries PM; Iking-Konert C Dtsch Med Wochenschr; 2014 Jun; 139(23):1234-6. PubMed ID: 24866957 [No Abstract] [Full Text] [Related]
12. [Vasculitis]. Fleck M; Hellmich B Dtsch Med Wochenschr; 2011 Jun; 136(22):1194-6. PubMed ID: 21611928 [No Abstract] [Full Text] [Related]
13. Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? Flossmann O; Jones RB; Jayne DR; Luqmani RA Ann Rheum Dis; 2006 Jul; 65(7):841-4. PubMed ID: 16769779 [TBL] [Abstract][Full Text] [Related]